Back to Authors

Veglio, Franco

https://orcid.org/0000-0002-5239-6890

A5012452729 | I55143463

Mayo Clinic

Division of Internal Medicine & Hypertension Center, Department of Medical Sciences, AO Città Salute e Scienza, University of Torino, Torino, Italy

Citations 2

Genome-Wide Association Study Identifies CAMKID Variants Involved in Blood Pressure Response to Losartan: The Sophia Study

Pharmacogenomics | November 20, 2014 | Volume: 15 | Issue: 13 | Pages: 1643-1652

10.2217/pgs.14.119 | PMID 25410890

Increased Diagnosis of Primary Aldosteronism, Including Surgically Correctable Forms, in Centers from Five Continents

The Journal of Clinical Endocrinology & Metabolism | March 4, 2004 | Volume: 89 | Issue: 3 | Pages: 1045-1050

10.1210/jc.2003-031337 | PMID 15001583

Abstract Primary aldosteronism (PA) is a common form of endocrine hypertension previously believed to account for less than 1% of hypertensive patients. Hypokalemia was considered a prerequisite for pursuing diagnostic tests for PA. Recent studies applying the plasma aldosterone/plasma renin activity ratio (ARR) as a screening test have reported a higher prevalence. This study is a retrospective evaluation of the diagnosis of PA from clinical centers in five continents before and after the widespread use of the ARR as a screening test. The application of this strategy to a greater number of hypertensives led to a 5- to 15-fold increase in the identification of patients affected by PA. Only a small proportion of patients (between 9 and 37%) were hypokalemic. The annual detection rate of aldosterone-producing adenoma (APA) increased in all centers (by 1.3–6.3 times) after the wide application of ARR. Aldosterone-producing adenomas constituted a much higher proportion of patients with PA in the four centers that employed adrenal venous sampling (28–50%) than in the center that did not (9%). In conclusion, the wide use of the ARR as a screening test in hypertensive patients led to a marked increase in the detection rate of PA.